Enables New Cost Model

The risks of patient exposure to pathogenic agents that may cause transfusion-transmitted infectious disease (TTI) have not been eliminated by current blood safety measures. These risks remain inherent throughout the process of collecting, testing, manufacturing and distributing platelets for transfusion.

The INTERCEPT™ Blood System for platelets is intended for the ex vivo pathogen inactivation of whole-blood-derived and apheresis platelet. The system is used to inactivate a broad spectrum of viruses, bacteria, protozoa and contaminating donor leukocytes in platelets components.

The introduction of INTERCEPT enables a new cost model for blood component production. Conventional safety measures rely on adding new screening and testing methods as new threats emerge, entering a cycle of ever-increasing production costs. Effective pathogen inactivation with INTERCEPT stops this cycle and can lead to cost savings through the removal of redundant safety measures.

The INTERCEPT Blood System for platelets has been designed to treat single or multiple units of platelet concentrates. To maximise the efficiency of the INTERCEPT treatment process, the I-Platelet pooling kit enables the pooling of up to eight buffy coats to produce multiple platelet transfusion doses.